NCT06585488 - A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification | Biotech Hunter

Enrollment

514

Participants

Timeline

Start Date

November 26, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Metastatic Solid TumorsAdvanced Non-squamous Non-small-cell Lung CancerAdvanced Colorectal CancerAdvanced Pancreatic Ductal AdenocarcinomaAdvanced Gastric CancerAdvanced Gastroesophageal Junction CancerAdvanced Esophageal Adenocarcinoma

Interventions

DRUG

BGB-53038

Administered orally

DRUG

Tislelizumab

administered by intravenous infusion

DRUG

Cetuximab

administered by intravenous infusion

Trial Locations (17)

1023

RECRUITING

Auckland City Hospital, Auckland

13620

RECRUITING

Seoul National University Bundang Hospital, BundangGu SeongnamSi

21287

RECRUITING

Sidney Kimmel Comprehensive Cancer At Johns Hopkins, Baltimore

100021

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

100142

RECRUITING

Beijing Cancer Hospital, Beijing

90089-1019

RECRUITING

Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles

66160-8500

RECRUITING

University of Kansas Medical Center Research Institute, Kansas City

77030-4009

RECRUITING

The University of Texas Md Anderson Cancer Center, Houston

NSW 2148

RECRUITING

Blacktown Cancer and Haematology Centre, Blacktown

VIC 3168

RECRUITING

Monash Health, Clayton

VIC 3000

RECRUITING

Peter Maccallum Cancer Centre, Melbourne

WA 6009

RECRUITING

Linear Clinical Research, Nedlands

030013

RECRUITING

Shanxi Provincial Cancer Hospital, Taiyuan

06351

RECRUITING

Samsung Medical Center, GangnamGu

03722

RECRUITING

Severance Hospital Yonsei University Health System, SeodaemunGu

03080

RECRUITING

Seoul National University Hospital, Seoul

05505

RECRUITING

Asan Medical Center, SongpaGu